Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
IR_propancbiopharma
IR_propancbiopharma Mar. 20 at 6:02 PM
$PPCB Advancing a new therapy into human clinical testing requires coordinated progress across science, manufacturing, and regulatory preparation. As our Director of Research and Development, Dr. Ralf Brandt, explained: “Establishing and validating our PK method for the First-In-Human study is one of three key activities in preparation for this milestone, alongside GMP manufacturing of PRP and the clinical trial application for the study.” Our collaboration with FyoniBio represents one of these important steps as we continue building the analytical and operational framework required to support the upcoming clinical program for PRP. As Propanc aligns its manufacturing, regulatory, and analytical work, we take coordinated progress toward entering human trials. These preparations are what ultimately enable future value‑creating clinical milestones.
0 · Reply
WaveRider666
WaveRider666 Mar. 20 at 11:58 AM
$PPCB - I see $PPCB IR is back, pumping the Hell out of this endlessly toxic diluting POS. Don't listen to the propaganda. The long term chart tells you everything you need to know about this scam. ps - learn to trade Futures and then you'll never want to touch these toxic diluting stinky pinkies ever again!
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 8:06 PM
$PPCB As we move closer to initiating our Phase 1b First-In-Human study, establishing the right analytical capabilities is an essential part of the development process. Through our collaboration with FyoniBio, we are developing a liquid chromatography–mass spectrometry (LC-MS) pharmacokinetics assay designed to quantify PRP and its analytes in patient serum over time. The method is expected to detect concentrations with a sensitivity of at least 0.1 µg/mL, allowing researchers to closely track the therapy following administration. These measurements will help our research team understand how PRP behaves in the body while monitoring patient response throughout the clinical study. Developing a sensitive PK assay is essential for generating reliable data once the trial begins. These technical foundations help support stronger clinical outcomes down the line.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 7:35 PM
$PPCB Conventional treatments for aggressive cancers such as Pancreatic Cancer often face the same obstacles: toxicity, resistance, and limited long-term effectiveness. PRP is being developed with a different objective. Our proenzyme therapy is designed to influence malignant cells to differentiate while potentially increasing tumor sensitivity to standard chemotherapy. By addressing biological drivers linked to metastasis and recurrence, this approach may complement existing treatment strategies. After more than 17 years of research and development, our focus at Propanc Biopharma is now on translating this scientific work into clinical progress. As we move closer to human trials, we remain committed to disciplined execution and transparent updates.
0 · Reply
KOWALSK1
KOWALSK1 Mar. 18 at 6:54 AM
0 · Reply
KOWALSK1
KOWALSK1 Mar. 17 at 10:45 AM
$PPCB ✅️ BUY ZONE 0.14 to 0.11 ✋️ RISK BELOW 0.09 💲PT. 0.16 0.23 0.30 0.34 0.47 + UP Follow for more
0 · Reply
supermanme
supermanme Mar. 16 at 5:58 PM
$PPCB gaining momentum
0 · Reply
Wubai
Wubai Mar. 16 at 5:49 AM
$PPCB Sometimes you strike gold by digging through the trash—this one reeks, but I’m going for it!🤣🤣
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 13 at 8:31 PM
$PPCB Pancreatic cancer remains one of the most difficult diseases in oncology, with a five year survival rate of just 13% and limited therapeutic progress over the past decade. This is the challenge our team at Propanc Biopharma has been working to address. Our lead therapy PRP continues to demonstrate encouraging preclinical results. In pancreatic cancer models, PRP achieved greater than 85% tumor growth inhibition, while also reducing fibrosis and resistance markers in the tumor microenvironment, two key factors that often limit treatment effectiveness. These findings reinforce the scientific rationale behind our program as we continue preparing for our planned Phase 1b First-In-Human clinical study. We look forward to sharing additional milestones. Let us know if you have any questions.
0 · Reply
Golibajje
Golibajje Mar. 13 at 4:55 PM
$RPGL Watch out this one! Singapore play!! Cash around $10M.. trading at $2.8m!!  THIS could run like $ELPW.. 500% on a single day!! $EJH $PPCB $DTCK
1 · Reply
Latest News on PPCB
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 9 days ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 11 days ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 18 days ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 4 weeks ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 6 weeks ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 7 weeks ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 3 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 3 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 3 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 4 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 4 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 4 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 5 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 5 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 5 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 6 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 7 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 7 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 7 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

IR_propancbiopharma
IR_propancbiopharma Mar. 20 at 6:02 PM
$PPCB Advancing a new therapy into human clinical testing requires coordinated progress across science, manufacturing, and regulatory preparation. As our Director of Research and Development, Dr. Ralf Brandt, explained: “Establishing and validating our PK method for the First-In-Human study is one of three key activities in preparation for this milestone, alongside GMP manufacturing of PRP and the clinical trial application for the study.” Our collaboration with FyoniBio represents one of these important steps as we continue building the analytical and operational framework required to support the upcoming clinical program for PRP. As Propanc aligns its manufacturing, regulatory, and analytical work, we take coordinated progress toward entering human trials. These preparations are what ultimately enable future value‑creating clinical milestones.
0 · Reply
WaveRider666
WaveRider666 Mar. 20 at 11:58 AM
$PPCB - I see $PPCB IR is back, pumping the Hell out of this endlessly toxic diluting POS. Don't listen to the propaganda. The long term chart tells you everything you need to know about this scam. ps - learn to trade Futures and then you'll never want to touch these toxic diluting stinky pinkies ever again!
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 8:06 PM
$PPCB As we move closer to initiating our Phase 1b First-In-Human study, establishing the right analytical capabilities is an essential part of the development process. Through our collaboration with FyoniBio, we are developing a liquid chromatography–mass spectrometry (LC-MS) pharmacokinetics assay designed to quantify PRP and its analytes in patient serum over time. The method is expected to detect concentrations with a sensitivity of at least 0.1 µg/mL, allowing researchers to closely track the therapy following administration. These measurements will help our research team understand how PRP behaves in the body while monitoring patient response throughout the clinical study. Developing a sensitive PK assay is essential for generating reliable data once the trial begins. These technical foundations help support stronger clinical outcomes down the line.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 7:35 PM
$PPCB Conventional treatments for aggressive cancers such as Pancreatic Cancer often face the same obstacles: toxicity, resistance, and limited long-term effectiveness. PRP is being developed with a different objective. Our proenzyme therapy is designed to influence malignant cells to differentiate while potentially increasing tumor sensitivity to standard chemotherapy. By addressing biological drivers linked to metastasis and recurrence, this approach may complement existing treatment strategies. After more than 17 years of research and development, our focus at Propanc Biopharma is now on translating this scientific work into clinical progress. As we move closer to human trials, we remain committed to disciplined execution and transparent updates.
0 · Reply
KOWALSK1
KOWALSK1 Mar. 18 at 6:54 AM
0 · Reply
KOWALSK1
KOWALSK1 Mar. 17 at 10:45 AM
$PPCB ✅️ BUY ZONE 0.14 to 0.11 ✋️ RISK BELOW 0.09 💲PT. 0.16 0.23 0.30 0.34 0.47 + UP Follow for more
0 · Reply
supermanme
supermanme Mar. 16 at 5:58 PM
$PPCB gaining momentum
0 · Reply
Wubai
Wubai Mar. 16 at 5:49 AM
$PPCB Sometimes you strike gold by digging through the trash—this one reeks, but I’m going for it!🤣🤣
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 13 at 8:31 PM
$PPCB Pancreatic cancer remains one of the most difficult diseases in oncology, with a five year survival rate of just 13% and limited therapeutic progress over the past decade. This is the challenge our team at Propanc Biopharma has been working to address. Our lead therapy PRP continues to demonstrate encouraging preclinical results. In pancreatic cancer models, PRP achieved greater than 85% tumor growth inhibition, while also reducing fibrosis and resistance markers in the tumor microenvironment, two key factors that often limit treatment effectiveness. These findings reinforce the scientific rationale behind our program as we continue preparing for our planned Phase 1b First-In-Human clinical study. We look forward to sharing additional milestones. Let us know if you have any questions.
0 · Reply
Golibajje
Golibajje Mar. 13 at 4:55 PM
$RPGL Watch out this one! Singapore play!! Cash around $10M.. trading at $2.8m!!  THIS could run like $ELPW.. 500% on a single day!! $EJH $PPCB $DTCK
1 · Reply
Marcovich2000
Marcovich2000 Mar. 13 at 4:14 PM
$PPCB This corpse of a company will be trading at under $.01 in no time, once the delisting is announced.
0 · Reply
i_like_bb_stock
i_like_bb_stock Mar. 13 at 3:36 PM
$PPCB took a starter here, doji candle on the daily selling has subsided, should see a nice bounce
0 · Reply
supermanme
supermanme Mar. 13 at 2:49 PM
$PPCB looks like bottom is in
1 · Reply
Rexracer13
Rexracer13 Mar. 13 at 10:10 AM
$PPCB how is this stock still trading. It should be on the pink sheets.
0 · Reply
Cendaaaaaaaaaa
Cendaaaaaaaaaa Mar. 12 at 3:56 PM
$PPCB up 1 dolar
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 12 at 3:10 PM
$PPCB We are pleased to share another important step forward as we continue preparing for our Phase 1b First-In-Human clinical study evaluating PRP in patients with advanced solid tumors. Propanc Biopharma has executed a service agreement with FyoniBio GmbH, a Berlin-based Contract Development Organization that supports biotech companies advancing biologics from early development into the clinic. Under this agreement, FyoniBio will establish and validate a liquid chromatography–mass spectrometry (LC-MS) pharmacokinetics assay. This assay will enable our team to measure PRP levels in patient serum during the study, generating key data on drug exposure, safety, and tolerability as we advance our lead product candidate toward its first clinical evaluation in humans. This agreement signals that Propanc is steadily completing the core requirements needed to begin human testing. Each step like this strengthens the path toward clinical milestones.
0 · Reply
BullyJimmy
BullyJimmy Mar. 12 at 1:00 PM
$PPCB when in doubt, zoom out. Trillion 🤣 R/S master
0 · Reply
Mrious
Mrious Mar. 12 at 12:57 PM
$PPCB be careful. A bunch of pumpers just entered the board. Usually bad news
1 · Reply
MrTicker
MrTicker Mar. 12 at 12:57 PM
$PPCB Propanc Biopharma, Inc. (PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology's most desperate battlegrounds with a grim 13% five-year survival rate. Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game: - >85% tumor growth inhibition demonstrated in preclinical pancreatic models - Forces malignant cells to differentiate—attacking cancer at its root - Reduces fibrosis and resistance markers in the tumor microenvironment - Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity - Targets cancer stem cells to cut recurrence risk
0 · Reply
MrTicker
MrTicker Mar. 12 at 12:56 PM
$PPCB Propanc Biopharma Highlights PRP Proenzyme Therapy Aimed At $3B+ Pancreatic Cancer Market With Grim 13% Survival Rate BENZINGA 7:55 AM ET 3/12/2026
0 · Reply
BigPennyStockAlerts
BigPennyStockAlerts Mar. 12 at 12:48 PM
$PPCB- $0.14 Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 12 at 12:47 PM
$PPCB Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
0 · Reply